Download Baxter International Inc.

Baxter International Inc.
About our Cover:
Kanyakorn Piasukho of Bangkok, Thailand, was diagnosed with
chronic nephritis in infancy and experienced acute kidney failure
in 2009. She relies on Baxter peritoneal dialysis products as she
awaits a possible kidney transplant.
1
Baxter International Inc.
Baxter International Inc. innovates, develops, manufactures
and markets products for people with hemophilia, immune
disorders, infectious diseases, kidney disease, trauma, and
other chronic and acute medical conditions. The company’s
diverse portfolio is focused on treatments that save and sustain
lives. As a global, diversified healthcare company, Baxter
applies a unique combination of expertise in medical devices,
pharmaceuticals and biotechnology to research and create
products that advance patient care worldwide.
2
Worldwide Presence
Thomas Polzer, research scientist at Baxter’s Orth, Austria, facility,
conducts validation experiments on the company’s investigational
recombinant factor IX product for patients with hemophilia B.
3
4
A Pioneer in Healthcare
therapeutic proteins, IV and
Baxter has been a healthcare leader for more than 80
years with a rich history of medical “firsts.” The company
was responsible for the first commercially manufactured
intravenous (IV) solutions, the first commercial kidney
dialysis system, the first factor VIII concentrate to treat
hemophilia and many other medical breakthroughs.
More recent firsts include the first recombinant factor VIII
processed with no blood-based additives and the first
cell culture-derived pandemic influenza vaccine.
dialysis solutions and devices,
Life-Saving Products
Innovation is the driving force
behind Baxter’s success. The
company is a technology leader in
recombinant and plasma-derived
drug delivery systems, and
other technologies.
Baxter products are infused, injected or inhaled more than
two billion times annually (or six million times a day), each
time to treat a life-threatening acute or chronic condition.
Patients with hemophilia, end-stage kidney disease, primary
immune deficiency and a range of other diseases depend
on Baxter products. This creates a common purpose among
Baxter’s approximately 48,500 employees worldwide: to
save and sustain lives.
Ten-year-old Brenden Broyles of Denver, Colorado, a primary immunodeficiency patient, was a participant in Baxter’s clinical trial of an
investigational therapy designed to provide subcutaneous infusion of immune globulin through a single injection site at volumes, intervals
and rates comparable to intravenous infusion.
Worldwide Presence
5
Scientific Capabilities
Manufacturing Strength
Innovation is the driving force behind Baxter’s success.
The company is a technology leader in the research
and development of recombinant and plasma-derived
therapeutic proteins, IV and dialysis solutions and
devices, drug packaging and delivery systems,
and other technologies. Baxter’s businesses share
expertise in medical plastics, biologics, sterilization
and other scientific disciplines to create a range of
life-saving products.
Baxter’s manufacturing strength and commitment
to quality are foundations of the company. With
more than 50 production facilities in 27 countries,
proprietary technologies, and complementary
manufacturing platforms across its businesses,
Baxter can produce high-quality products
cost-effectively for local and regional markets,
helping improve healthcare quality worldwide.
A Socially Responsible Citizen
Global Scope
Baxter products are sold in more than 100 countries,
with approximately 60 percent of the company’s revenues
coming from outside the United States. Baxter’s greatest
growth opportunities are in developing and emerging
markets, where many people with life-threatening
conditions are under-treated. As the economies of these
countries continue to develop, Baxter is poised to meet
their healthcare needs.
Simone von Fircks (left), research and development senior
manager, and Irene Kinzl, research scientist, use state of the
art imaging technology to select cells used in Baxter therapies
at the company’s Orth, Austria, facility.
Part of being a great company is being a responsible
corporate citizen. Baxter gives back to the communities
it serves through environmental stewardship, employee
volunteerism, corporate giving and other initiatives.
Baxter has been recognized for its commitment to
sustainability, the company’s long-term strategic
approach to including social, economic and
environmental considerations and opportunities
to achieve its business objectives and contribute
to a more sustainable world.
Children in the Campo Limpo region of São Paulo, Brazil, receive
dental care and education thanks to Projeto Arrastão, a recipient
of a grant from The Baxter International Foundation.
6
Moris de Boer of Rotterdam, the Netherlands, has multifocal motor
neuropathy (MMN), a chronic disease characterized by progressive
weakness in the limbs. Baxter produces the only centrally licensed
treatment across the European Union for MMN.
7
BioScience
Baxter’s BioScience business develops recombinant and plasmabased proteins to treat hemophilia and other bleeding disorders;
plasma-based therapies to treat immune deficiencies, alpha-1
antitrypsin deficiency, burns and shock, and other blood-related
conditions; products for regenerative medicine, such as proteins
used to promote hemostasis and wound-sealing in surgery; and
selected vaccines.
In 1941, Baxter introduced the first system for separating plasma
from whole blood and storing it for later use. Plasma contains a
number of proteins that serve various therapeutic purposes. The
company later became a leader in plasma fractionation – the
process of breaking down plasma into its component parts – to
produce a range of plasma-derived therapeutic proteins. In the
1990s, Baxter added recombinant technology to its capabilities,
enabling the company to produce some therapeutic proteins, such
as factor VIII for hemophilia, in cell culture rather than through
plasma fractionation. Baxter’s BioScience business continues to
advance medical science to research and develop new and better
life-saving products and therapies for patients.
8
Hemophilia
Baxter’s BioScience business
continues to advance medical
science to develop new and
better life-saving products and
therapies for patients.
Baxter is a leading developer of clotting factors to treat
hemophilia. This includes recombinant and plasma-based
factor VIII – the clotting protein missing from the blood of
people with hemophilia A – and therapies for people that
develop inhibitors against clotting factor. Baxter also has a
number of research and development programs aimed at
improving the treatment of hemophilia and other bleeding
disorders. These include a longer-acting (PEGylated) form
of a full-length recombinant factor VIII protein, recombinant
factor IX therapy for hemophilia B, a recombinant therapy
for inhibitor patients and the first recombinant therapy for
von Willebrand disease.
In 2011, Gilberto Jiménez Chávez of Mexico City experienced extreme bleeding during surgery to remove a brain tumor. Surgeons used
a Baxter-produced hemostatic matrix to help control the bleeding.
BioScience
9
BioTherapeutics
BioSurgery
Baxter is a leading provider of immunoglobulin therapies for
patients with immune deficiencies. These plasma-derived
therapies provide antibody replacement for patients
whose immune systems do not produce enough antibodies
to fight infection. In addition to primary immunodeficiency,
the therapy also is being investigated for use in neurological
conditions, such as Alzheimer’s disease. In Europe,
the therapy has been approved to treat multifocal motor
neuropathy, a degenerative disease that attacks the
peripheral nerves, resulting in progressive limb weakness.
Other products include albumin, a plasma-volume
expander used to treat burns and maintain adequate fluid
volume in critical care patients, and alpha1-proteinase
inhibitor to treat alpha-1 antitrypsin deficiency, a respiratory
condition that can result in early onset emphysema.
In recent years, Baxter has attained technological
leadership in the research and development of biosurgery
products – biological and chemical products used to stop
bleeding and seal wounds in surgery – and technologies
to facilitate hard tissue regeneration in orthobiologics and
soft tissue repair used in a variety of surgical procedures.
The company’s stem cell technologies are being explored
for their potential to restore blood flow in patients with
cardiovascular and peripheral artery disease.
Bill Garten of Mission, Texas, participated in a Baxter Phase II
trial that found that injections of a patient’s own CD34+ stem
cells reduced chest pain and improved exercise ability in
patients with severe angina due to chronic myocardial ischemia.
Vaccines
Baxter provides vaccines for meningitis C, tick-borne
encephalitis, and seasonal and pandemic influenza.
Baxter’s Vero cell technology, used in flu vaccine
production, offers potential advantages over traditional
egg-based vaccine production methods.
FDA approval of a prophylaxis indication for a Baxter recombinant
factor VIII treatment for hemophilia A supports patients like Jay
Brown of Baton Rouge, Louisiana, in infusing treatment to prevent
bleeds in addition to infusing treatment after bleeds occur.
10
Teeramanas Tanaekakarapong of Bangkok, Thailand, has had end-stage
kidney disease since 2007. He relies on Baxter peritoneal dialysis
products to maintain his normal day-to-day work and leisure activities.
11
Medical Products
Baxter’s Medical Products business manufactures products used
in the delivery of fluids and drugs to patients. These include
intravenous (IV) solutions and administration sets, premixed drugs
and drug-reconstitution systems, pre-filled vials and syringes
for injectable drugs, IV nutrition products, infusion pumps, and
inhalation anesthetics. The business also is a leader in homebased renal therapies, such as peritoneal dialysis, and offers other
products and services for people with end-stage kidney disease.
In 1931, Baxter introduced the first commercially produced IV
solutions, premixed in glass containers and shipped ready for use.
Baxter later introduced the world’s first flexible, plastic IV containers
and became the first company to partner with pharmaceutical firms
to premix their drugs in IV solutions for safe and efficient delivery
to patients. In recent years, Baxter’s expertise in medication
delivery has extended to IV nutrition products, infusion pumps
and inhalation anesthetics. In renal therapy, Baxter introduced the
first commercially built artificial kidney in 1956, making life-saving
dialysis possible for people with end-stage kidney disease, and
later helped commercialize peritoneal dialysis, the first home-based
dialysis therapy.
12
Fluid Systems
Baxter is the world’s leading provider of commercially
prepared IV solutions as well as frozen and ready-to-use
premixed drugs in flexible IV containers. Baxter’s portfolio
of IV solutions and premixed drugs is the broadest in the
industry. The company also provides IV infusion pumps
and administration sets, which control the delivery of IV
fluids and drugs to patients.
and mineral formulas. The company also is a leader in
anesthesia and sells the three most commonly used
modern inhaled anesthetics for general anesthesia.
Baxter’s Specialty Pharmaceuticals portfolio includes a
short-acting, cardioselective-adrenergic blocker (beta
blocker) used to control heart rate in patients who are at
high risk for cardiac events during and after surgery.
Renal
Specialty Pharmaceuticals
Baxter is a leading developer of products for parenteral,
or IV, nutrition, which provides life-sustaining support for
patients who cannot receive adequate nutrients orally or
through other means. Baxter offers one of the broadest
portfolios of parenteral nutrition, including solutions,
container systems, admixing technologies, vitamins
Baxter is also a leading developer of products for
peritoneal dialysis (PD), a home-based therapy for people
with end-stage kidney disease. Products include PD
solutions, automated cyclers, connectivity devices and
ancillary supplies. In addition, the company distributes
products for hemodialysis (HD), which generally takes
place in a hospital or clinic, and is developing a home HD
Until receiving a kidney transplant, Jim McFarlin of Champaign, Illinois, used automated peritoneal dialysis products from Baxter to
cleanse his blood of toxins and waste normally removed by healthy kidneys.
Medical Products
13
platform, which will provide another option for dialysis
patients. Baxter also provides products for continuous
renal replacement therapy, typically performed in the
intensive care unit of a hospital, to treat acute renal failure.
BioPharma Solutions
Baxter advances the clinical and commercial development
of innovative drug and drug formulation technologies
through contract manufacturing. Products include prefilled
injectable drugs in vials and syringes, lyophilized drugs,
and biologics such as proteins and antibodies for
biotechnology and pharmaceutical companies.
Baxter’s Medical Products
business manufactures products
used in the delivery of fluids and
drugs to patients. In recent years,
Baxter’s expertise in medication
delivery has extended to IV
nutrition products, infusion pumps
and inhalation anesthetics.
Nurse Heather Evans of Southlake Regional Health Centre in
Newmarket, Ontario, Canada, administers parenteral nutrition
using one of Baxter’s triple-chamber container systems.
Pharmacy technician Sophia Hohenberg uses a Baxter
compounder to custom mix parenteral nutrition solutions at
Children’s Mercy Hospital and Clinic in Kansas City, Missouri.
14
Baxter Facts in Brief
Deerfield, Illinois, USA
1931
Established
C O R P O R AT E H E A D Q U A R T E R S
48,500
A P P RO X I M AT ELY
employees
worldwide
Businesses: BioScience, Medical Products
BAXTER PRODUCTS ARE USED IN:
Hospitals / Surgery centers and other outpatient clinics / Kidney dialysis centers / Doctors’ offices /
Nursing homes / Rehabilitation centers / Clinical and medical research laboratories / At home
under physician supervision /
United States
2011
SALES
Latin America
and Canada
Asia-Pacific
$13.89
billion
$1,685
$2,107
2011
Sales by Region
(millions)
Europe
$4,392
$5,709
15
RES E A R C H A N D D E V EL OPM ENT
M ANUFACT UR I N G
Research and development (R&D) is essential to
Baxter manufactures
products in 27 countries:
Baxter’s growth. These activities are performed at
R&D centers around the world, including facilities in
Australia
Austria, Belgium, Japan and the United States, as
Austria
well as in conjunction with select R&D partners.
2011 R&D Investment:
$946 million
Belgium
Brazil
Canada
Chile
China
Colombia
Operations
Baxter has operations (including offices and manufacturing/
distribution facilities) in 62 countries. The company
conducts business in more than 100 countries.
Costa Rica
Czech Republic
Germany
India
Ireland
Italy
Japan
Malta
Mexico
Philippines
Sustainability
Baxter has been recognized by many sustainability-related
organizations. In 2011, Baxter was named:
Poland
Saudi Arabia
Singapore
Spain
Switzerland
• to the Dow Jones Sustainability Index for the 13th straight year,
and the Medical Products leader for the 10th time
• one of the Global 100 Most Sustainable Corporations by Corporate
Knights Inc.
• to Fortune magazine’s list of the World’s Most Admired Companies
Tunisia
Turkey
United Kingdom
United States,
including Puerto Rico
• fourth overall in Newsweek magazine’s “Green Rankings” of the 500
largest U.S. companies, and first globally in the healthcare category
• to the 100 Best Corporate Citizens list by Corporate Responsibility magazine
Baxter is a registered trademark of
Baxter International Inc.
16
Baxter History of Firsts
1941
First plasma-collection
and storage unit
1998
First triple-chamber
container system for
parenteral nutrition
1968
First commercially
produced factor VIII
concentrate to treat
hemophilia
1977
First therapy for people
with hemophilia who
develop antibodies
against clotting factor
1956
First commercially
built artificial kidney
2005
First albumin in a
flexible, plastic
container
1979
First automated
blood-cell separator
1982
First heat-treated factor
VIII, reducing risk of
viral transmission
1978
First ambulatory
dialysis system
1939
First sterile bloodcollection container
1974
First premixed
IV drugs
1931
First commercially
manufactured IV
solutions
1992
First recombinant
factor VIII
1991
First needle-less
system for IV
therapy
1971
First flexible, plastic IV
container
1959
First flexible, plastic
blood-collection system
1988
First factor VIII
purified by chemical
and monoclonal
techniques
2009
First cell culture-based
pandemic influenza
vaccine
2011
First triple-chamber
container system for
parenteral nutrition
designed specifically
for pediatric patients
2007
First needle-less
IV connector
with an antimicrobial
coating
2003
First recombinant factor
VIII made without
any added human or
animal proteins
Design: paragraphs.com
© Baxter International Inc., 2012. All rights reserved. References in this report to Baxter are intended to refer collectively
to Baxter International Inc. and its U.S. and international subsidiaries.
Baxter International Inc.
One Baxter Parkway
Deerfield, Illinois 60015-4625
USA
www.baxter.com
Regional Headquarters Locations
Europe, Middle East and Africa
Baxter Healthcare SA
P.O. Box
CH-8010 Zürich
Switzerland
Asia Pacific
Baxter (China) Investment Co. Ltd.
10F Platinum Tower
233 Tai Cang Road
Shanghai, 200020
China
Latin America/Canada
Baxter Export Corporation
101 Northeast 3rd Avenue, Suite 1600
Fort Lauderdale, FL 33301-1181
USA
Printed on recycled paper containing 10% post-consumer recovered fiber using soy-based inks.